271 related articles for article (PubMed ID: 18047776)
1. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies.
Harris ST; Blumentals WA; Miller PD
Curr Med Res Opin; 2008 Jan; 24(1):237-45. PubMed ID: 18047776
[TBL] [Abstract][Full Text] [Related]
2. Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.
Miller PD; Recker RR; Harris S; Silverman S; Felsenberg D; Reginster J; Day BM; Barr C; Masanauskaite D
Osteoporos Int; 2014 Jan; 25(1):349-57. PubMed ID: 24136103
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
4. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.
Cranney A; Wells GA; Yetisir E; Adami S; Cooper C; Delmas PD; Miller PD; Papapoulos S; Reginster JY; Sambrook PN; Silverman S; Siris E; Adachi JD
Osteoporos Int; 2009 Feb; 20(2):291-7. PubMed ID: 18663402
[TBL] [Abstract][Full Text] [Related]
5. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
6. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Rossini M; Viapiana O; Gatti D; Adami S
Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
[TBL] [Abstract][Full Text] [Related]
7. Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA.
Sambrook P; Cranney A; Adachi JD
Curr Med Res Opin; 2010 Mar; 26(3):599-604. PubMed ID: 20055751
[TBL] [Abstract][Full Text] [Related]
8. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.
Bianchi G; Czerwinski E; Kenwright A; Burdeska A; Recker RR; Felsenberg D
Osteoporos Int; 2012 Jun; 23(6):1769-78. PubMed ID: 21975558
[TBL] [Abstract][Full Text] [Related]
9. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis.
Sebba AI; Emkey RD; Kohles JD; Sambrook PN
Bone; 2009 Mar; 44(3):423-7. PubMed ID: 19049913
[TBL] [Abstract][Full Text] [Related]
10. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
[TBL] [Abstract][Full Text] [Related]
11. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
Felsenberg D; Miller P; Armbrecht G; Wilson K; Schimmer RC; Papapoulos SE
Bone; 2005 Nov; 37(5):651-4. PubMed ID: 16126016
[TBL] [Abstract][Full Text] [Related]
12. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Epstein S; Jeglitsch M; McCloskey E
Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
[TBL] [Abstract][Full Text] [Related]
13. Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy.
Amling M; Kurth A
Womens Health (Lond); 2009 Sep; 5(5):467-73. PubMed ID: 19702445
[TBL] [Abstract][Full Text] [Related]
14. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
Reginster JY
Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
[TBL] [Abstract][Full Text] [Related]
15. Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application.
Cole RE; Harris ST
Medscape J Med; 2009; 11(1):12. PubMed ID: 19295933
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
Lee YH; Song GG
Korean J Intern Med; 2011 Sep; 26(3):340-7. PubMed ID: 22016595
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
Reginster JY; Adami S; Lakatos P; Greenwald M; Stepan JJ; Silverman SL; Christiansen C; Rowell L; Mairon N; Bonvoisin B; Drezner MK; Emkey R; Felsenberg D; Cooper C; Delmas PD; Miller PD
Ann Rheum Dis; 2006 May; 65(5):654-61. PubMed ID: 16339289
[TBL] [Abstract][Full Text] [Related]
18. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
Schimmer RC; Bauss F
Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
McClung MR; Bolognese MA; Sedarati F; Recker RR; Miller PD
Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
[TBL] [Abstract][Full Text] [Related]
20. Beyond daily dosing: clinical experience.
Cooper C
Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
